Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Operating Leases

Microsoft Excel

An operating lease is treated like a rental contract. Neither the leased asset nor the associated liability is reported on the lessee balance sheet, but the rights may be very similar to the rights of an owner. The lessee only records the lease payments as a rental expense in income statement.


Adjustments to Financial Statements for Operating Leases

Abbott Laboratories, adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Total Assets
Total assets (as reported) 86,713 81,414 73,214 74,438 75,196
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Total assets (adjusted) 86,713 81,414 73,214 74,438 75,196
Adjustment to Total Debt
Total debt (as reported) 12,929 14,125 14,679 16,773 18,050
Add: Operating lease liability (before adoption of FASB Topic 842)2
Add: Operating lease liability, current (included in Other accrued liabilities) 276 254 245 230 245
Add: Operating lease liability, non-current 931 896 949 943 956
Total debt (adjusted) 14,136 15,275 15,873 17,946 19,251

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1, 2 Equal to total present value of future operating lease payments.


Abbott Laboratories, Financial Data: Reported vs. Adjusted



Adjusted Financial Ratios for Operating Leases (Summary)

Abbott Laboratories, adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Total Asset Turnover1
Reported total asset turnover 0.51 0.52 0.55 0.59 0.57
Adjusted total asset turnover 0.51 0.52 0.55 0.59 0.57
Debt to Equity2
Reported debt to equity 0.25 0.30 0.38 0.46 0.50
Adjusted debt to equity 0.27 0.32 0.41 0.49 0.54
Return on Assets3 (ROA)
Reported ROA 7.52% 16.46% 7.82% 9.31% 9.40%
Adjusted ROA 7.52% 16.46% 7.82% 9.31% 9.40%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

Financial ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Abbott Laboratories adjusted total asset turnover ratio deteriorated from 2023 to 2024 and from 2024 to 2025.
Adjusted debt to equity A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. Abbott Laboratories adjusted debt to equity ratio improved from 2023 to 2024 and from 2024 to 2025.
Adjusted ROA A profitability ratio calculated as net income divided by adjusted total assets. Abbott Laboratories adjusted ROA improved from 2023 to 2024 but then deteriorated significantly from 2024 to 2025.

Abbott Laboratories, Financial Ratios: Reported vs. Adjusted



Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net sales 44,328 41,950 40,109 43,653 43,075
Total assets 86,713 81,414 73,214 74,438 75,196
Activity Ratio
Total asset turnover1 0.51 0.52 0.55 0.59 0.57
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Net sales 44,328 41,950 40,109 43,653 43,075
Adjusted total assets 86,713 81,414 73,214 74,438 75,196
Activity Ratio
Adjusted total asset turnover2 0.51 0.52 0.55 0.59 0.57

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Net sales ÷ Total assets
= 44,328 ÷ 86,713 = 0.51

2 Adjusted total asset turnover = Net sales ÷ Adjusted total assets
= 44,328 ÷ 86,713 = 0.51

Activity ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Abbott Laboratories adjusted total asset turnover ratio deteriorated from 2023 to 2024 and from 2024 to 2025.


Adjusted Debt to Equity

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total debt 12,929 14,125 14,679 16,773 18,050
Total Abbott shareholders’ investment 52,130 47,664 38,603 36,686 35,802
Solvency Ratio
Debt to equity1 0.25 0.30 0.38 0.46 0.50
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Adjusted total debt 14,136 15,275 15,873 17,946 19,251
Total Abbott shareholders’ investment 52,130 47,664 38,603 36,686 35,802
Solvency Ratio
Adjusted debt to equity2 0.27 0.32 0.41 0.49 0.54

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= 12,929 ÷ 52,130 = 0.25

2 Adjusted debt to equity = Adjusted total debt ÷ Total Abbott shareholders’ investment
= 14,136 ÷ 52,130 = 0.27

Solvency ratio Description The company
Adjusted debt-to-equity A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. Abbott Laboratories adjusted debt-to-equity ratio improved from 2023 to 2024 and from 2024 to 2025.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net earnings 6,524 13,402 5,723 6,933 7,071
Total assets 86,713 81,414 73,214 74,438 75,196
Profitability Ratio
ROA1 7.52% 16.46% 7.82% 9.31% 9.40%
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Net earnings 6,524 13,402 5,723 6,933 7,071
Adjusted total assets 86,713 81,414 73,214 74,438 75,196
Profitability Ratio
Adjusted ROA2 7.52% 16.46% 7.82% 9.31% 9.40%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net earnings ÷ Total assets
= 100 × 6,524 ÷ 86,713 = 7.52%

2 Adjusted ROA = 100 × Net earnings ÷ Adjusted total assets
= 100 × 6,524 ÷ 86,713 = 7.52%

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as net income divided by adjusted total assets. Abbott Laboratories adjusted ROA improved from 2023 to 2024 but then deteriorated significantly from 2024 to 2025.